Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine in Older Patients with AML Unsuitable for Intensive Chemotherapy
NCT00924443Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2004
- Primary completion
- Jun 2006
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of clofarabine in acute myeloid leukemia (AML), sponsored by Sanofi. Primary endpoint: Overall Response Rate at 20 months. Started Jun 2004; status: completed.
02
Drugs
clofarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00924443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00924443.